Fusion molecules

Patent metadata

Field	Value
Publication number	US-10316071-B2
Application number	US-201615203613-A
Country	US
Kind code	B2
Filing date	Jul 6, 2016
Priority date	Jul 7, 2015
Publication date	Jun 11, 2019
Grant date	Jun 11, 2019

Abstract

The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.

First claim

What is claimed is:

1. A fusion molecule having binding specificity for pyoverdine type I, II and III and pyochelin, comprising (a) a first polypeptide comprising a first human neutrophil gelatinase-associated lipocalin (hNGAL) mutein that binds pyoverdine type 1; (b) a second polypeptide comprising a second hNGAL mutein that binds pyoverdine type II; (c) a third polypeptide comprising a third hNGAL mutein that binds pyoverdine type III; and (d) a fourth polypeptide comprising a fourth hNGAL mutein that binds pyochelin; wherein the first, second, third and fourth polypeptides are covalently linked, wherein the first hNGAL mutein comprises 10 or more mutations at positions 28, 36, 39-41, 46, 49, 52, 54, 55, 59, 65, 68, 70, 72-75, 77, 79-81, 87, 96, 100, 103, 106, 125, 127, 132, 134, and 136 of SEQ ID NO: 1; the second hNGAL mutein comprises 10 or more mutations at positions 36, 40, 49, 52, 54, 65, 68, 70, 72, 73, 77, 79, 81, 87, 103, 106, 125, 127, 132, and 134 of SEQ ID NO: 1, the third hNGAL mutein comprises 10 or more mutations at positions 36, 40, 41, 42, 49, 52, 65, 68, 70, 73, 77, 79, 81, 87, 96, 100, 103, 105, 106, 127, and 134 of SEQ ID NO: 1; and the fourth hNGAL mutein comprises 10 or more mutations at positions 36, 40, 41, 45, 46, 49, 52, 65, 68, 70, 72, 73, 77, 79, 81, 87, 100, 103, 106, 125, 127, 132, and 134 of the linear polypeptide sequence of the mature hNGAL (SEQ ID NO: 1).

2. The fusion molecule of claim 1 , wherein the first, second, third, and fourth hNGAL mutein binds pyoverdine type I, pyoverdine type II, pyoverdine type III and pyochelin, respectively, each with a dissociation constant K D of 200 nM or lower.

3. The fusion molecule of claim 1 , wherein the first, second, third and fourth polypeptides are covalently linked via linker molecules.

4. The fusion molecule of claim 3 , wherein the linker molecules are peptide linkers.

5. The fusion molecule of claim 1 , further comprising a multimerization domain allowing multimerization of the fusion molecule.

6. The fusion molecule of claim 5 , wherein the multimerization domain is a dimerization domain allowing the dimerization of the fusion molecule.

7. The fusion molecule of claim 6 , wherein the dimerization domain is selected from the group consisting of an Fc domain, an IgE heavy-chain domain 2 (EHD2), an IgM heavy-chain domain 2 (MHD2), an IgG heavy-chain domain 3 (GHD3), an IgA heavy-chain domain 3 (AHD2), an IgD heavy-chain domain 3 (DHD3), an IgE heavy-chain domain 4 (EHD4), an IgM heavy-chain domain 4 (MHD4), an uteroglobin dimerization domain and variants or fragments of any one of the foregoing.

8. The fusion molecule of claim 7 , wherein the Fc domain is a human IgG4-Fc domain.

9. The fusion molecule of claim 1 , having a general formula selected from the group consisting of
N′-X 1 -L 1 -X 2 -L 2 -X 3 -L 3 -X 4 -C′  (I),

N′-X 1 -L 1 -X 2 -L 2 -X 3 -L 3 -X 4 -L 4 -MD-C′  (II),

N′-MD-L 1 -X 1 L 2 -X 2 -L 3 -X 3 -L 4 -X 4 -C′  (III),

N′-X 1 -L 1 -X 2 -L 2 -MD-L 3 -X 3 -L 4 -X 4 -C′  (IV),

N′-X 1 -L 1 -MD-L 2 -X 2 -L 3 -X 3 -L 4 -X 4 -C′  (V), and

N′-X 1 -L 1 -X 2 -L 2 -X 3 -L 3 -MD-L 4 -X 4 -C′  (VI)

wherein
X 1 , X 2 , X 3 and X 4 are, at each occurrence, selected from the group consisting of the first, second, third and fourth polypeptides, with the proviso that the fusion molecule comprises each of the first, second, third and fourth polypeptides;
MD comprises a multimerization domain; and
L 1 , L 2 , L 3 and L 4 are, at each occurrence, independently selected from a covalent bond and a linker molecule.

10. The fusion molecule of claim 1 , being present as a multimeric complex.

11. The fusion molecule of claim 1 , wherein the fusion molecule has one or more of the following properties:
(i) it further comprises at least one label or tag allowing the detection and/or isolation of the fusion molecule;
(ii) it further comprises one or more modifications increasing the stability of the fusion molecule and/or extending the serum half-life of the fusion molecule;
(iii) it inhibits or reduces iron uptake by P. aeruginosa through pyochelin and/or pyoverdine;
(iv) it inhibits or reduces virulence factor expression by P. aeruginosa;
(v) it inhibits or reduces pyochelin- and/or pyoverdine-mediated signalling;
(vi) it inhibits or reduces P. aeruginosa bacterial growth; and
(vii) it is associated with or conjugated/fused to a pharmaceutically active agent.

12. The fusion molecule of claim 11 , wherein the pharmaceutically active agent is selected from the group consisting of an antibiotic, a cytostatic agent, a toxin, a metal or metal compound/complex, a chelating agent, a hapten and an antibody.

13. A pharmaceutical composition comprising the fusion molecule of claim 1 .

14. A kit comprising a fusion molecule of claim 1 .

15. A fusion molecule having binding specificity for pyoverdine type I, II and III and pyochelin, comprising
(a) a first polypeptide comprising a first hNGAL mutein that binds pyoverdine type I consisting of SEQ ID NO: 16;
(b) a second polypeptide comprising a second hNGAL mutein that binds pyoverdine type II consisting of SEQ ID NO: 36;
(c) a third polypeptide comprising a third hNGAL mutein that binds pyoverdine type III consisting of SEQ ID NO: 53; and
(d) a fourth polypeptide comprising a fourth hNGAL mutein that binds pyochelin consisting of SEQ ID NO: 62;
wherein the first, second, third and fourth polypeptides are covalently linked.

Assignees

• Sanofi Sa

Inventors

• Corvey Carsten
• Stump Heike
• Kruip Jochen
• Lange Christian
• Focken Ingo
• Rat Dorothea
• Stuedemann Thomas
• Rasser Hans-Falk
• Schaefer Juergen
• Calandra Bernard
• Rey Astrid
• Mourez Michael
• Fraisse Laurent
• Rothe Christine
• Allersdorfer Andrea
• Wiedenmann Alexander
• Hinner Marlon
• Lunde Bradley
• Jensen Kristian
• Hülsmeyer Martin

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• C07K2319/22

  containing a Strep-tag · CPC title